Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Acute anti-Aβ antibody exposure induces microglial changes and significantly alters chemokine signaling.

Alzheimer's & dementia (New York, N. Y.)·2026

Same author

MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics.

Annals of neurology·2025

Same author

Acute Communication Between Microglia and Nonparenchymal Immune Cells in the Anti-Aβ Antibody-Injected Cortex.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2024

Same author

Soluble Biomarkers of Cerebrovascular Pathologies.

Stroke·2024

Same author

Alzheimer's disease and inflammatory biomarkers positively correlate in plasma in the UK-ADRC cohort.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2023

Same author

Mechanisms of ARIA: is it time to focus on the unique immune environment of the neurovascular unit?

Molecular neurodegeneration·2023

Same journal

Update on Genetic Chorea.

Current neurology and neuroscience reports·2026

Same journal

Gastrointestinal Dysfunction in Critically Ill Patients With Traumatic Brain Injury: Clinical Implications and Putative Mechanisms: a Narrative Review.

Current neurology and neuroscience reports·2026

Same journal

The Potential of Rehabilitation to Amplify Experience-Induced Myelin Plasticity and Remyelination in Multiple Sclerosis: A Narrative Review.

Current neurology and neuroscience reports·2026

Same journal

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026

Same journal

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026

Same journal

Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.

Current neurology and neuroscience reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 24, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Vascular Considerations for Amyloid Immunotherapy.

Kate E Foley¹, Donna M Wilcock²

¹Sanders-Brown Center On Aging, Department of Physiology, University of Kentucky, Lexington, KY, USA.

Current Neurology and Neuroscience Reports

|October 21, 2022

Summary

This summary is machine-generated.

Anti-amyloid beta (Aβ) immunotherapies aim to clear brain plaques in Alzheimer's disease (AD) but often cause concerning vascular issues like ARIA. Further research is crucial for safer AD treatments.

Keywords:

Aducanumab Alzheimer’s disease Amyloid Biomarkers Immunotherapy Vascular

More Related Videos

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Related Experiment Videos

Last Updated: Aug 24, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Area of Science:

Neuroscience
Immunology
Neurology

Background:

Amyloid beta (Aβ) plaque accumulation is a key pathology in Alzheimer's disease (AD), linked to cognitive decline.
Anti-Aβ immunotherapies are a major research focus for clearing these plaques.
Cerebrovascular complications, specifically ARIA, are a significant concern with these therapies.

Purpose of the Study:

To review the historical development of anti-Aβ immunotherapies.
To analyze clinical findings related to these treatments.
To provide recommendations for future research and therapeutic strategies.

Main Methods:

Literature review of animal and human studies on anti-Aβ immunotherapies.
Analysis of clinical trial data and reported side effects.
Examination of the mechanisms underlying immunotherapy-induced vascular deficits.

Main Results:

Anti-Aβ immunotherapies have shown efficacy in reducing Aβ plaques over two decades.
Amyloid-related imaging abnormalities (ARIA), indicating cerebrovascular compromise, are frequently observed.
The precise mechanisms driving ARIA remain largely unknown.

Conclusions:

Despite Aβ clearance, anti-Aβ immunotherapies present significant challenges due to vascular side effects.
The recent approval of aducanumab highlights the urgent need to address these vascular deficits.
Future research must prioritize understanding and mitigating ARIA for safer AD treatment development.